Moleculin Biotech, Inc. — Q1 2021 Form 10-Q
Business context and period: Unaudited results for the three months ended March 31, 2021, compared with Q1 2020; balance-sheet figures are compared with December 31, 2020. Moleculin is a clinical-stage pharmaceutical company developing treatments for resistant cancers and viruses. It reported no revenue and operates as a single segment.
Financial performance and liquidity
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $4.105 million | $3.206 million |
| General and administrative expense | $1.939 million | $1.810 million |
| Total operating expenses / operating loss | $6.088 million / $(6.088) million | $5.062 million / $(5.062) million |
| Net loss | $(4.445) million | $(1.209) million |
| Net loss per share, basic and diluted | $(0.20) | $(0.15) |
| Cash used in operating activities | $(3.624) million | $(4.342) million |
| Cash and cash equivalents | $86.293 million | $15.173 million at Dec. 31, 2020 |
| Total assets / total liabilities | $99.784 million / $11.268 million | $29.031 million / $11.271 million at Dec. 31, 2020 |
Gross and operating margins are not meaningful because the company had no revenue. The filing reports no conventional interest-bearing borrowings; liabilities included a $6.563 million long-term warrant liability and $0.249 million in operating lease liabilities. Current assets were $88.019 million against current liabilities of $4.578 million.
Changes versus the prior period and financing
- R&D expense increased $0.899 million, primarily reflecting more clinical-trial activity, sponsored research, and drug-product manufacturing. G&A rose $0.129 million.
- Net loss widened by $3.236 million. The $1.577 million noncash gain from revaluing warrant liabilities was smaller than the $3.845 million gain in Q1 2020, while operating expenses increased.
- Operating cash use declined by $0.718 million, primarily because accounts payable increased. Financing provided $74.748 million, largely from a February public offering and underwriter option exercise, plus January ATM sales and warrant exercises. The public offering raised approximately $78.0 million gross; the ATM raised approximately $2.9 million gross.
- Cash increased $71.120 million during the quarter. Common shares outstanding rose from 11,536,720 at year-end to 28,444,425 at March 31, 2021, reflecting substantial equity issuance. The company effected a 1-for-6 reverse stock split in January; share figures are presented retroactively for the split.
Outlook, developments, and risks
- Management said March 31 cash was expected to fund projected operating requirements through at least 2023, including a forecast increase in R&D spending. The company expects operating losses and negative operating cash flow for several years; further financing may be needed, with no assurance it will be available on acceptable terms.
- The company anticipated four or more new clinical trials in 2021, in addition to three continuing trials. Plans included Annamycin trials in AML and soft-tissue-sarcoma lung metastases, WP1122 clinical development, and continued WP1066 work. Timing and regulatory approvals were not assured.
- In the Poland Annamycin AML trial, preliminary results at 240 mg/m² showed clinical benefit in three patients who received the full dose; two other patients had transient elevated liver enzymes and discontinued treatment. The company planned a protocol amendment and further enrollment, subject to approval. These are preliminary findings, not established efficacy.
- The MD Anderson-sponsored adult WP1066 brain-tumor trial was expected to close after its physician sponsor left; Moleculin sought transfer of the IND and anticipated a temporary delay. The Emory pediatric trial was proceeding to its next dose cohort.
- COVID-19 had slowed recruitment and restricted monitoring at some Polish sites, though the company reported limited improvement in recruitment and limited drug-supply interruption. Third-party manufacturing, trial recruitment, regulatory outcomes, intellectual-property licenses, and the ability to obtain financing remain important risks.
- Management reported effective disclosure controls as of March 31, 2021, with no material change in internal control over financial reporting. No legal proceedings were reported.
Important facts for investors to verify
- Whether planned clinical trials began on schedule and whether recruitment, safety, and efficacy results support continued development.
- How long the $86.3 million cash balance supports operations as clinical and R&D spending increases, and whether additional capital will be required.
- The extent of dilution from the 2021 equity raise and any future stock or warrant issuance.
- Whether the Annamycin protocol amendment is accepted and how subsequent safety findings affect dose escalation.
- Whether COVID-19, third-party manufacturing, licensing, or regulatory delays materially affect trial timelines or costs.